Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for DAPK2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | DAPK2 Kinase Domain / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Sf9 or E. coli expressed. |
View DAPK2 Products |
| Gene Delivery | DAPK2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression assays. |
View DAPK2 Products |
| Benchmark Ab | Anti-DAPK2 Recombinant Antibody Recombinant positive control for Western Blot, IHC, and ELISA. |
View DAPK2 Products |
| Validator | DAPK2 siRNA Set For knockdown verification and target specificity validation. |
View DAPK2 Products |
| Related Target A | DAPK1 Homologous family member; essential for selectivity counter-screening. |
View DAPK1 Products |
| Related Target B | DAPK3 Homologous family member (ZIPK); critical for profiling kinase inhibitor cross-reactivity. |
View DAPK3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Kinase Subfamily Selectivity | Active DAPK1, DAPK2, and DAPK3 recombinant proteins available with >95% purity for robust counter-screening. |
| Calcium/Calmodulin Dependency | Sequence-verified catalytic domains produced to ensure consistent response to Ca2+/Calmodulin activation. |
| Lack of Controls | Clinical-grade benchmark antibodies and recombinant proteins included for assay calibration. |
| False Positives | Validated siRNA sets included to confirm target-specific knockdown in phenotypic cell-based assays. |
Live DAPK2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of Death-Associated Protein Kinase 2 (DAPK2) is gaining traction as its role in regulating apoptosis, autophagy, and granulocyte differentiation becomes clearer. As a calcium/calmodulin-regulated serine/threonine kinase, DAPK2 acts as a double-edged sword: its downregulation or silencing is associated with cancer progression (such as acute myeloid leukemia), while its hyperactivation contributes to inflammatory pathologies and neurodegenerative diseases.
The race for DAPK2 therapeutics is intensifying, with major players shifting focus from traditional broad-spectrum kinase inhibitors to highly selective small molecules. As first-generation therapies reach preclinical validation, the next wave of R&D is targeting allosteric modulation and isoform-specific inhibition to avoid off-target toxicities associated with other DAPK family members.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic institutions, Biotech startups | Neurodegeneration, Inflammatory disorders | Selectivity Assay (Need high-purity DAPK1, DAPK2, and DAPK3 proteins to ensure zero cross-reactivity) |
| Gene Therapy / mRNA | Oncology-focused biopharma | Acute Myeloid Leukemia (AML), Solid Tumors | Expression Validation (Need DAPK2 Lentivirus for stable cell line construction and phenotypic rescue) |
| Allosteric Modulators | Structure-based drug design firms | Ischemic tissue injury, Cancer | Conformational assays (Need Sequence Verified, high-purity proteins with intact regulatory domains) |